# Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

> **NCT01922089** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 498 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT01922089
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 498 (ACTUAL)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01922089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01922089, "Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01922089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*